entity

GWAS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about GWAS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections

8Hypotheses

5Analyses

1Outgoing

0Incoming

2Experiments

7Debates

No AI portrait yet

Wiki Pages (4)

Knowledge base pages for this entity

Canonical Page

Outgoing (1)

Target	Relation	Type	Str
Alzheimer's disease	associated_with	disease	0.70

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (8)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
PD-Associated GWAS Variants in CTSO and CTSF Genes Create a	0.743	neurodegeneration	-
VEGF-family genetic control of vascular-neuronal coupling in	0.626	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc
DPP6-linked neuronal regulatory networks controlling synapti	0.626	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Cell-state stratification is required to resolve DPP6 GWAS S	0.612	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Cell-state stratification is required to resolve VEGF Family	0.612	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc

Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc
Tau-trafficking GWAS loci define a druggable PTK2B endocytos	0.600	Alzheimer's disease	-

Mentioning Analyses (5)

Scientific analyses that reference this entity

LRRK2 Risk Variants: Lysosomal Membrane Dynamics in DA vs Striatal Neurons

neurodegeneration | 2026-04-27 | 0 hypotheses

DPP6 GWAS Signal: Cell-Type Regulatory Networks for PD Cognitive Decline

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.626

VEGF Family GWAS Signals and Cerebrovascular-Neuronal Coupling in AD Hippocampus

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.626

Statistical Fine-Mapping of AD GWAS Loci to Identify Causal Variants

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.380

Variant Annotation and Prioritization of AD Risk Loci

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.862

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
12 newly identified AD-associated genes show prior evidence linking th	computational	Alzheimer's disease	0.500	0.00	in_vitro	extracted	N/A
Experiment: Multi-Ethnic PD GWAS	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,500,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (7)

Multi-agent debates referencing this entity

How do VEGF family gene variants identified by single-cell GWAS analysis alter c

active · Rounds: 4 · Score: 0.67 · 2026-04-28

What cell-type-specific gene regulatory networks mediate the DPP6 GWAS signal fo

active · Rounds: 4 · Score: 0.67 · 2026-04-28

How do GWAS-identified PD risk variants at the LRRK2 locus alter lysosomal membr

active · Rounds: 6 · Score: 0.89 · 2026-04-27

Which non-coding variants at AD GWAS loci have functional evidence for gene regu

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Can Bayesian fine-mapping of the top 25 AD GWAS loci identify credible sets of c

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Does fine-mapping to median 3-variant credible sets provide sufficient resolutio

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Does the BIN1 non-coding variant mechanism provide a druggable target, or is tra